P-glycoprotein activity in renal clear cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 4, 2009, Pages 363-366

  Soto Vega, Elena ^a   Arroyo, Carlos ^b   Richaud Patin, Yvonne ^c   García Carrasco, Mario ^a   Vázquez Lavista, Luis G ^c   Llorente, Luis ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Chemoresistance; Daunorubicin; Multidrug resistance; P glycoprotein; Renal cancer

Indexed keywords

DAUNORUBICIN; GLYCOPROTEIN P; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER TISSUE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCUBATION TEMPERATURE; INCUBATION TIME; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; MULTIDRUG RESISTANCE; NEPHRECTOMY; PRIORITY JOURNAL; THERAPY RESISTANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; FLOW CYTOMETRY; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; P-GLYCOPROTEIN;

EID: 67649336584     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.01.011     Document Type: Article

References (30)

1. Jemal A., Murray T., and Ward E. Cancer statistics. CA Cancer J Clin 55 (2005) 10-30
2. Vogelzang N.J., and Stadler W.M. Kidney cancer. Lancet 352 (1998) 1691-1696
3. Hock L.M., Lynch J., and Balaji K.C. Increasing incidence of all stages of kidney cancer in the last two decades in the United States: An analysis of surveillance, epidemiology and end results program data. J Urol 167 (2002) 57-60
4. Ramsey S., and Aitchinson M. Treatment for renal cell: Are we beyond the cytokine era?. Nat Clin Pract Urol 3 (2006) 478-484
5. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
6. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
7. Inui K., Masuda S., and Satio H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 58 (2000) 944-958
8. Chang G. Multidrug resistance ABC transporters. FEBS Lett 27 (2003) 102-105
9. Liang X.J., and Aszalos A. Multidrug transporters as drug targets. Curr Drug Targets 7 (2006) 911-921
10. Tsuruo T. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep 67 (1983) 889-894
11. Ueda K., Cardarelli C., Gottesman M.M., et al. Expression of a full length cDNA from the human MDR-1 gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84 (1987) 3004-3008
12. Juranka P.F., Zastawny R.L., and Ling V. P-glycoprotein: Multidrug resistance and a superfamily of membrane-associated transport proteins. FASEB J 324 (1989) 485-489
13. Bradley G., Naik M., and Ling V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res 49 (1989) 2790-2796
14. Hill B.T., Deuchars K., and Hosking L.K. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractioned X irradiation in vitro. J Natl Cancer Inst 82 (1990) 607-612
15. McClean S., and Hill B.T. Evidence of post-translational regulation of P-glycoprotein associated with expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells. Eur J Cancer 29A (1993) 2243-2248
16. Cornwell M.M., Pastan I., and Gottesman M.M. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane besides and inhibit drug binding to P-glycoprotein. J Biol Chem 262 (1987) 2166-2170
17. Safa A.R. Photoaffinity labeling of the multidrug resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci 85 (1998) 7187-7191
18. Safa A.R., Glover C.J., Sewell J.L., et al. Identification of the multidrug resistance-related membrane glycoprotein as acceptor for calcium channel blockers. J Biol Chem 262 (1987) 7884-7888
19. McCoy J.P., and Keren D.F. Current practices in clinical flow cytometry. A practice survey by the American Society of clinical pathologist. Am J Pathol 111 (1999) 161-168
20. Mathew A., Devesa S.S., Fraumeni J.F., et al. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 11 (2002) 171-178
21. Nguyen M.M., Gill I.S., and Ellison L.M. The evolving presentation of renal carcinoma in the United States: Trends from the surveillance, epidemiology and end results program. J Urol 176 (2006) 2397-2400
22. Lipworth L., Tarone R.E., and McLaughlin J.K. The epidemiology of renal cell carcinoma. J Urol 176 (2006) 2353-2358
23. Fojo T. Multiple paths to a drug resistance phenotype mutations, translocations, deletions and amplifications of coding genes or promoter regions, epigenetic changes and micro RNAs. Drug Resist Update 10 (2007) 59-67
24. Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 446 (2007) 749-757
25. Huff L.M., Lee J.S., Robey R.W., et al. Characterization of gene rearrangements leading to activation of MDR-1. J Biol Chem 281 (2006) 36501-36509
26. Harada T., Nagayama J., Kohno K., et al. Alu-associated interstitial deletions and chromosomal rearrangements in two human multidrug-resistant cell lines. Int J Cancer 86 (2000) 506-511
27. Asakura T., Imai A., Ohkubo-Uraoka N., et al. Relationship between expression of drug-resistance factors and drug sensitivity in normal human renal proximal tubular epithelial cells in comparison with renal cell carcinoma. Oncol Rep 14 (2005) 601-607
28. Mignogna C., Staibano S., Altieri V., et al. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: A five-year follow-up analysis. BMC Cancer 6 (2006) 293-303
29. Aouali N., Eddabra L., Macadré J., et al. Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hematol 56 (2005) 61-70
30. Bates S.E. Solving the problems of multidrug resistance: ABC transporters in clinical oncology. In: Holland I.B., Cole S.P., Kuchler K., et al. (Eds). ABC proteins: From bacteria to man (2002), Elsevier Science, London 670-678